Our search revealed that 31 FDA-approved and 144 experimental drugs target 8 of the 22 MM products (HGF, CCND1, DKK1, EDNRB, VCAM1, ADM, CCL3, CXCL12) (Supplementary Table 6). This evidence concerns the gene CCND1 and Miyoshi myopathy.